IMGT Co.,Ltd. engages in researching and developing of an ultrasound-guided therapy technology for genetic therapy and drug delivery systems. It develops IMGT-LPS, a technology that injects ultrasound-sensitive nanoparticles in the form of liposome-wrapped pharmacological substances into the body and releases drugs by irradiating ultrasound to the target area(tumor); IMGT-EMB, a nanoparticle for chemoembolization of liver cancer; IMGT-TSD, a targeted sonodynamic therapy that induces immune boosting mechanism by applying ultrasonic stimulation to the cancerous area; and IMGT-FUS, a device for non-invasive treatment. The company was founded in 2010 and is based in Seongnam-si, South Korea.